Academic Journal
Προβολή σε EDS

Mapping the NEI-VFQ-25 scores to the EQ-5D-Y-3L and CHU-9D utility values among adolescents with myopia.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Mapping the NEI-VFQ-25 scores to the EQ-5D-Y-3L and CHU-9D utility values among adolescents with myopia.
Συγγραφείς: Luo C; School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.; Institute of Health Economics and Policy, Tianjin University, Tianjin, China., Liu M; College of Pharmaceutical Sciences, Southwest University, Chongqing, China., Shao R; School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.; Institute of Health Economics and Policy, Tianjin University, Tianjin, China., Xie S; School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China. xiest@tju.edu.cn.; Institute of Health Economics and Policy, Tianjin University, Tianjin, China. xiest@tju.edu.cn., Wu J; School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China. jingwu@tju.edu.cn.; Institute of Health Economics and Policy, Tianjin University, Tianjin, China. jingwu@tju.edu.cn.
Πηγή: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [Qual Life Res] 2026 Jul 23; Vol. 35 (9). Date of Electronic Publication: 2026 Jul 23.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Springer Netherlands Country of Publication: Netherlands NLM ID: 9210257 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-2649 (Electronic) Linking ISSN: 09629343 NLM ISO Abbreviation: Qual Life Res Subsets: MEDLINE
Imprint Name(s): Publication: 2005- : Netherlands : Springer Netherlands
Original Publication: Oxford, UK : Rapid Communications of Oxford, Ltd, c1992-
Ιατρικοί όροι (MeSH): Myopia*/psychology , Quality of Life*/psychology , Sickness Impact Profile*, Surveys and Questionnaires/standards ; Humans ; Adolescent ; Female ; Male ; China ; Algorithms
Περίληψη: Purpose: To develop mapping algorithms for predicting EQ-5D-Y-3L and CHU-9D utility values from the National Eye Institute 25-Item Visual Function Questionnaire (NEI-VFQ-25) among adolescents with myopia to support economic evaluation.
Methods: Data were collected from 2,198 adolescents with myopia in China. Conceptual overlap was assessed using Spearman's rank correlation. Six regression models, including ordinary least squares (OLS), Tobit, censored least absolute deviations (CLAD), generalized linear model (GLM), two-part model (TPM), and adjusted limited dependent variable mixture model (ALDVMM), were evaluated. The predictors included the NEI-VFQ-25 total score and the subscale scores. Model performance was assessed via five-fold cross-validation and random sample validation based on mean absolute error (MAE), root mean squared error (RMSE), Akaike information criterion (AIC), Bayesian information criterion (BIC), and the proportions of absolute error (AE) > 0.05. Sensitivity analyses of model validation were conducted.
Results: The mean (SD) utility values were 0.962 (0.070) for the EQ-5D-Y-3L and 0.851 (0.160) for the CHU-9D. The NEI-VFQ-25 total score correlated moderately with the CHU-9D (r = 0.50) but weakly with the EQ-5D-Y-3L (r = 0.37). The OLS and GLM using stepwise-selected subscale scores demonstrated the best predictive performance for EQ-5D-Y-3 L (MAE = 0.045, RMSE = 0.061, AE > 0.05 [%] = 30.37%) and CHU-9D (MAE = 0.103, RMSE = 0.139, AE > 0.05 [%] = 61.50%), respectively. Sensitivity analyses generally supported the primary model-selection results.
Conclusion: This study established algorithms for estimating EQ-5D-Y-3L and CHU-9D utility values based on NEI-VFQ-25 subscale scores for adolescents with myopia, thus facilitating future economic evaluation for myopia interventions. However, given the limited conceptual overlap between the NEI-VFQ-25 and EQ-5D-Y-3L, the EQ-5D-Y-3L algorithm should be applied with caution.
(© 2026. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Competing Interests: Declarations. Competing interests: The authors declare no competing interests. Role of the Funder: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Ethics approval: This study was approved by the Tianjin Eye Hospital, Tianjin, China (No. KY-2023025), and was conducted in accordance with the Declaration of Helsinki. Instrument permissions: Permission to use all instruments included in this study was obtained from their respective instrument owners. Consent to participate: Informed consent was obtained from all individual participants and their parents included in the study. Participants were informed about their freedom of refusal. Anonymity and confidentiality were maintained throughout the research process. Consent for publication: Participants agreed to the publication of the research results using their anonymous data.
References: JAMA. 2015 Sep 15;314(11):1137-9. (PMID: 26372581)
BMC Public Health. 2025 Oct 9;25(1):3452. (PMID: 41068823)
Lancet. 2012 May 5;379(9827):1739-48. (PMID: 22559900)
Qual Health Res. 2010 Mar;20(3):340-51. (PMID: 20054040)
Ophthalmic Epidemiol. 2014 Apr;21(2):66-78. (PMID: 24568628)
Value Health. 2022 Nov;25(11):1910-1921. (PMID: 35752534)
Health Qual Life Outcomes. 2025 Apr 30;23(1):46. (PMID: 40307906)
Front Cardiovasc Med. 2023 Mar 09;10:1074969. (PMID: 36970361)
Optom Vis Sci. 2008 Nov;85(11):1091-9. (PMID: 18981924)
Health Qual Life Outcomes. 2007 Dec 21;5:70. (PMID: 18154669)
Qual Life Res. 2010 Aug;19(6):875-86. (PMID: 20405245)
Value Health. 2021 Mar;24(3):443-460. (PMID: 33641779)
Eur J Health Econ. 2010 Apr;11(2):215-25. (PMID: 19585162)
Qual Life Res. 2016 Feb;25(2):275-281. (PMID: 26231589)
Optom Vis Sci. 2016 Dec;93(12):1495-1501. (PMID: 27575991)
Ophthalmol Ther. 2022 Oct;11(5):1655-1680. (PMID: 35809192)
JAMA. 2015 Sep 15;314(11):1142-8. (PMID: 26372583)
Qual Life Res. 2010 Aug;19(6):887-97. (PMID: 20401552)
Ophthalmol Glaucoma. 2023 Sep-Oct;6(5):541-563. (PMID: 37142217)
Health Qual Life Outcomes. 2023 Feb 22;21(1):19. (PMID: 36814254)
PLoS One. 2014 Feb 20;9(2):e89222. (PMID: 24586607)
Qual Life Res. 2005 Aug;14(6):1523-32. (PMID: 16110932)
Dtsch Arztebl Int. 2016 Oct 14;113(41):693-702. (PMID: 27839543)
Patient. 2020 Oct;13(5):537-555. (PMID: 32382953)
Eye (Lond). 2012 Oct;26(10):1295-301. (PMID: 22766537)
Bone Jt Open. 2022 Jul;3(7):573-581. (PMID: 35837809)
Qual Life Res. 2019 Jan;28(1):163-176. (PMID: 30374777)
Health Qual Life Outcomes. 2024 Jul 29;22(1):59. (PMID: 39075537)
Health Qual Life Outcomes. 2019 Jul 8;17(1):117. (PMID: 31286982)
Health Qual Life Outcomes. 2024 Dec 5;22(1):105. (PMID: 39633400)
Adv Ophthalmol Pract Res. 2024 Mar 07;4(2):84-94. (PMID: 38623588)
PLoS One. 2017 Apr 17;12(4):e0175847. (PMID: 28414745)
Qual Life Res. 2024 Mar;33(3):817-829. (PMID: 38167749)
Qual Life Res. 2020 Sep;29(9):2529-2539. (PMID: 32297132)
J Glaucoma. 2018 Jul;27(7):585-591. (PMID: 29762270)
Arch Ophthalmol. 2001 Jul;119(7):1050-8. (PMID: 11448327)
Qual Life Res. 2009 Oct;18(8):1105-13. (PMID: 19693703)
Value Health. 2012 May;15(3):495-503. (PMID: 22583460)
Health Qual Life Outcomes. 2013 Apr 12;11:59. (PMID: 23587015)
Pharmacoeconomics. 2026 Feb;44(2):187-205. (PMID: 41182577)
JAMA. 2020 Aug 11;324(6):571-580. (PMID: 32780139)
Appl Health Econ Health Policy. 2026 Jan;24(1):65-85. (PMID: 40824559)
Health Qual Life Outcomes. 2020 Mar 2;18(1):49. (PMID: 32122369)
Pharmacoeconomics. 2015 Oct;33(10):993-1011. (PMID: 26232200)
Ophthalmic Epidemiol. 2023 Jun;30(3):239-248. (PMID: 35787736)
PLoS One. 2015 Oct 20;10(10):e0140419. (PMID: 26485393)
Value Health Reg Issues. 2025 Nov;50:101159. (PMID: 40706133)
Acta Ophthalmol. 2021 Jun;99(4):e480-e488. (PMID: 32940410)
Value Health. 2023 Feb;26(2):269-279. (PMID: 36096966)
Eur J Health Econ. 2025 Jun;26(4):577-588. (PMID: 39340752)
Br J Ophthalmol. 2025 Feb 24;109(3):362-371. (PMID: 39317432)
Value Health. 2026 Jan;29(1):100-107. (PMID: 40774595)
Value Health. 2020 Jul;23(7):928-935. (PMID: 32762995)
Pharmacoeconomics. 2022 Dec;40(Suppl 2):147-155. (PMID: 36396878)
Value Health. 2017 Jan;20(1):18-27. (PMID: 28212961)
Value Health. 2025 Dec;28(12):1900-1910. (PMID: 40738298)
Eur J Health Econ. 2025 Nov;26(8):1347-1368. (PMID: 40220214)
Health Qual Life Outcomes. 2020 Dec 17;18(1):389. (PMID: 33334351)
Grant Information: 72404205 National Natural Science Foundation of China
Contributed Indexing: Keywords: CHU-9D; EQ-5D-Y-3L; Mapping; Myopia; NEI-VFQ-25
Entry Date(s): Date Created: 20260723 Date Completed: 20260724 Latest Revision: 20261008
Update Code: 20261008
DOI: 10.1007/s11136-026-04344-3
PMID: 42493702
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1573-2649
DOI:10.1007/s11136-026-04344-3